International — European Commission & Pfizer

International — European Commission: The International — European Commission>>> previously granted marketing authorization for HYMPAVZI>>> for certain hemophilia patients, indicating broader international regulatory progress for the drug.

Pfizer: The expanded approval of HYMPAVZI by the United States — Food and Drug Administration>>> is a significant positive development for Pfizer>>>, enhancing its product portfolio and market reach in the hemophilia treatment space. This approval is expected to boost Pfizer>>>'s revenue and solidify its position as a leader in rare disease therapies.

International — European Commission: The International — European Commission facilitated the joint procurement, supporting member states' preparedness for RSV season and promoting mRNA vaccine use.

Pfizer: Pfizer's RSV vaccine Abrysvo faces increased competition from Moderna's mRESVIA in the EU market.

International — European Commission: Signed on as a member of the Coalition for Children's Rights and Protection in the Age of AI.

Pfizer: CEO Albert Bourla joined the AI for Good Global Commission.

International — European Commission: The International — European Commission is being investigated for its refusal to release messages from a secret group chat, which could harm its reputation for transparency and lead to calls for improved record-keeping practices.

Pfizer: Pfizer was mentioned in the context of a previous transparency dispute involving Ursula von der Leyen's text messages with its CEO, Albert Bourla, regarding COVID-19 vaccine contracts.

International — European Commission: Approved Palsonify for acromegaly in the EU.

Pfizer: Competitor in acromegaly market; PALSONIFY may compete with its treatments.